ANI Pharmaceuticals EPS Estimates Up to $8.38 for 2026; Shares Down 4% YTD
ANI Pharmaceuticals now holds a Zacks Rank #2 (Buy), with 2026 EPS forecasts raised from $8.20 to $8.38 and 2027 estimates lifted from $9.25 to $9.90 over the past 60 days. Despite a 4% year-to-date drop, shares have outperformed estimates in four straight quarters with a 22.21% average surprise.
1. Zacks Rank Upgrade
ANI Pharmaceuticals holds a Zacks Rank #2 (Buy), reflecting strong analyst confidence in its growth prospects and valuation relative to peers.
2. EPS Estimate Revisions
Over the past 60 days, consensus forecasts for 2026 EPS rose from $8.20 to $8.38, while 2027 EPS projections increased from $9.25 to $9.90, signaling improved profitability expectations.
3. Stock Performance
Despite upward estimate revisions, ANI Pharmaceuticals shares have declined 4% year-to-date, indicating market hesitation despite positive fundamental trends.
4. Earnings Surprise History
The company has beaten consensus in each of the last four quarters, delivering an average earnings surprise of 22.21%, underscoring its consistent operational execution.